Edgewise Therapeutics, Inc. reports developments from its muscle disease biopharmaceutical pipeline, including sevasemten for Becker and Duchenne muscular dystrophies and cardiac sarcomere modulators such as EDG-7500 and EDG-15400 for serious cardiac conditions. Company updates commonly cover clinical data presentations, open-label extension findings, trial-program progress, and financial results tied to research and development activity.
Recurring EWTX news also includes scientific-conference participation, Nasdaq inducement equity grants under the 2024 Inducement Equity Incentive Plan, and corporate communications about its focus on muscle physiology, dystrophinopathies, hypertrophic cardiomyopathy, and heart failure.
Edgewise Therapeutics (Nasdaq:EWTX) granted inducement stock options on May 29, 2026 to 4 new non-executive employees under its 2024 Inducement Equity Incentive Plan.
The options cover 74,000 shares at an exercise price of $34.16 per share and follow a four-year vesting schedule under Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (Nasdaq:EWTX) agreed to sell sevasemten and its muscular dystrophy business to Servier for $1.55 billion upfront plus up to $1.1 billion in milestones, totaling up to $2.65 billion. Edgewise will refocus on its cardiovascular pipeline (EDG-7500, EDG-15400, EDG-003). Upfront cash and existing funds are expected to fully finance EDG-7500 through potential approval. Edgewise plans 12-week CIRRUS-HCM Part D Phase 2 data in Q2 2026 and targets Phase 3 initiation in Q4 2026. A Phase 2 trial of EDG-15400 in HFpEF is also planned. Closing is expected in Q3 2026, subject to customary conditions and HSR clearance.
Servier agreed to acquire Edgewise Therapeutics' (Nasdaq:EWTX) muscular dystrophy business for up to $2.65 billion. The deal includes an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestones, and is expected to close in Q3 2026, subject to regulatory clearance.
The transaction adds sevasemten, an orally administered fast skeletal myosin inhibitor in a pivotal Becker muscular dystrophy cohort and phase 2 Duchenne study, along with associated neuromuscular capabilities.
Edgewise Therapeutics (Nasdaq:EWTX) announced that company leadership will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:00 am ET.
The presentation will be available via live webcast through the Edgewise Events & Presentations page and will remain accessible for replay for a limited time.
Edgewise Therapeutics (Nasdaq: EWTX) reported Q1 2026 results and clinical progress. Key facts: $499.6M cash, R&D $42.7M, G&A $11.5M, and net loss $49.0M ($0.46/sh). Clinical highlights include sevasemten stabilization up to 3.5 years, GRAND CANYON pivotal topline expected in Q4 2026, CIRRUS-HCM Part D data due Q2 2026, and planned Phase 3/Phase 2 starts in H2 2026.
Edgewise Therapeutics (Nasdaq: EWTX) announced inducement stock option grants on April 30, 2026, totaling 266,000 shares to nine new non-executive employees under its 2024 Inducement Equity Incentive Plan.
Each option has an exercise price of $30.96 (closing price on the grant date) and vests 25% after one year, then 1/48th monthly thereafter, subject to continued service. Grants were made as inducements under Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (Nasdaq: EWTX) announced inducement grants made March 31, 2026: 72,000 stock options were awarded to four new non‑executive employees under the 2024 Inducement Equity Incentive Plan.
Each option has an exercise price of $32.46 (closing price on the grant date) and vests 25% after one year, then 1/48th monthly thereafter, subject to continued service, granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Edgewise (Nasdaq: EWTX) reported long-term MESA open-label extension data for investigational sevasemten in Becker muscular dystrophy showing functional stabilization through 3.5 years on NSAA versus predicted declines from Becker natural history. Key numeric divergences: CANYON +0.1 vs predicted -2.9 (2 years) and ARCH +0.1 vs predicted -5.3 (3.5 years). Nearly 99% of eligible prior trial participants enrolled in MESA. Sevasemten maintained a favorable long-term safety profile. The placebo-controlled pivotal cohort, GRAND CANYON, is expected to read out in 4Q 2026, after which the company may pursue a marketing application if results are positive.
Edgewise Therapeutics (Nasdaq: EWTX) will present at the Leerink Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET. The company said the presentation will be webcast live and available for replay for a limited time.
Investors can find the webcast link on the Edgewise Events & Presentations page and are advised to connect several minutes early to ensure a timely connection.
Edgewise Therapeutics (Nasdaq: EWTX) will present new clinical and natural history data on sevasemten for Becker muscular dystrophy at the 2026 MDA Clinical and Scientific Conference in Orlando, March 8–11, 2026.
Edgewise will host a lunch forum on March 9 and showcase multiple scientific posters from March 8–10, including MESA open-label extension results and CANYON cardiac biomarker analyses. Presentations will be posted on the company website after the conference.